Astellas Korea – Jeong Hai-Do, President
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
Astellas Pharma Korea, Inc. is the Korean subsidiary of a leading global pharmaceutical company with outstanding R&D capabilities and a worldwide network.
Astellas has contributed to increasing the quality of life of customers by developing drugs to treat adult diseases and disorders such as urination disturbances common in men, frequent urination commonly in women, overactive bladder syndrome that causes frequent bathroom trips, as well as painful atopic dermatitis. The company also developed Gaster D, a gastroduodenal ulcer treatment drug, which has helped decrease the frequency of gastric ulcer surgery, and Prograf, and immunosuppression agent, which has improved the survival rate of organ transplant recipients.
Astellas Pharma Korea has been growing as a firm, taking pride in its contributions to customer quality of life, and provision of premium medicines in Korea, including Harnal, Vesicare, Prograf, and Protopic Ointment. It also a promising company in the mid-to-long term with many superb products awaiting further development, clinical testing, and launch. Astellas Pharma Korea does not aim to merely expand sales volume, but will continuously increase company value with the goal of maximizing added value for customers and thoseseeking better health, by establishing its Global Category Leader business model.
Contact details
6F 401 Hakdong-ro, Gangnam-gu, Seoul
+82 2 3448 0504
www.astellas.co.kr
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
Olive Healthcare is a startup developing wellness and medical devices services for the quantitative measurement of body composition, an integral part of the new healthcare paradigm based on prevention. Here,…
A Korean research team at Ulsan National Institute of Science and Technology (UNIST) have developed a cunning technology for treatments that attack cancer cells. Treatments that travel through the…
From Wednesday 31st October to Friday 2nd November, Seoul hosted the KoNECT-MFDS International conference, promoting South Korea’s clinical research capabilities on a global platform. The fourth of its kind, the…
Celltrion Healthcare, the marketing arm of the biopharmaceutical company Celltrion won a huge deal in France last Friday (2nd November 2018) with big tenders for Herzuma, a biosimilar of Roche’s…
Korea is fast becoming a big player in the pharmaceutical industry, especially within the biotech arena. With 4% of the total pipelines in the world, the country is showing strong…
Korean Pharma company, Hanmi has won orphan drug status this week from the US Food and Drug Administration (FDA) for HM43239, a drug for the treatment of acute myeloid leukaemia…
Local flagship company Boryung has found success with its newly developed angiotension receptor blocker (ARB) Kanarb. Nine molecules currently exist worldwide in this category of antihypertensives, and Kanarb is currently…
The growth of clinical trials in Korea has been remarkable in recent years. The number of clinical trials performed by multinationals has shot up from five in 2000 to 303…
Korea’s economy has been dominated for decades by chaebols, large family-owned business conglomerates like Samsung, Hyundai, and LG, known for their hierarchical structures and success in Korea’s traditional sectors. However,…
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
“When I left Janssen, I never imagined joining a Korean company,” recalls Choi Tae-Hung, sipping a freshly brewed yujacha tea in his office on a crisp autumn morning as he…
Minister Moon discusses the results of his recent state visit to the Middle East with Korea’s President, and Korea’s assets and potential as a global healthcare partner in developing and…
See our Cookie Privacy Policy Here
